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ABSTRACT 
Amino Acids in the First Transmembrane Domain Affecting Function of the Extracellular 
Domain of Truncated α4β2 Chimeras of the Nicotinic Acetylcholine Receptor. (May 2015) 
 
Adri Michelle Galvan 
Department of Biology 
Texas A&M University 
 
Research Advisor: Dr. Gregg Wells 
Department of Molecular and Cellular Medicine 
Texas A&M Health Science Center 
 
Important neurological and psychiatric diseases, including Alzheimer disease, nicotine addiction, 
and schizophrenia, are influenced by nicotinic acetylcholine receptors (nAChRs).  Understanding 
the structure and function of nAChRs will provide a foundation for developing drug therapies for 
these diseases.  nAChRs are members of the Cys-loop receptor superfamily.  Each nAChR 
contains five subunits with each subunit containing four transmembrane domains.  Once the 
ligand binds to the extracellular domain (ECD), the section of the nAChR that is exposed to the 
external environment, the protein undergoes a conformation change and an ion flux occurs 
allowing signal transmission.  The first transmembrane domain (M1) is specifically critical for 
the function of the neurotransmitter-binding ECD in nAChRs.  The features of M1 that are 
essential for ECD function, however, are not fully known.  M1 sequences from ionotropic 
serotonin (5HT3A) and from α4, β2, and α7 nAChR subunits are similar but behave differently 
in ECD α4β2 nAChRs.  The sequence differences provide the opportunity to discover amino 
acids from M1 that promote or inhibit ECD function.  Through site-directed mutagenesis and 
expression of chimeric M1 domains with extracellular α4 and β2 subunits in Xenopus oocytes, 
we determined amino acids in native M1 controlling expression of ECD α4β2 nAChRs and 
2 
 
amino acids from the 5HT3A M1 inhibiting that expression.  Generating a feasible ECD will 
provide insight into the essential properties allowing proper ligand binding, conformational 
changes, and in result the ion cascade triggering the receptor’s function.  The truncated designs 
of full length receptors will contribute to understanding how nAChR subunits fold and assemble 
and how their transmembrane domains affect structure and function.  The results will aid in 
identifying the importance of M1 in ECD function and guide the development of ECD Cys-loop 
receptors as water-soluble structural models of the full length receptors.  Water-soluble models 
are a key step in advancing our understanding of nAChRs due to the difficulty of producing high 
resolution structural models of full-length nAChR through crystallography.  With the 
advantageous physical properties of water-soluble protein, the shortcomings of crystallography 
with the full-length nAChRs would be overcome, allowing for further understanding of nAChR 
assembly, function, and future drug design. 
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NOMENCLATURE 
 
nAChR  Nicotinic Acetylcholine Receptor 
M1-M4  Transmembrane Domains 1-4 
5HT3A  Serotonin Receptor 
ECD   Extracellular Domain 
GluCl   Glutamate Receptor 
AChR   Acetylcholine Receptor 
NMR   Nuclear Magnetic Resonance 
AChBP  Acetylcholine Binding Protein 
ELIC   Erwinia chrysanthemi 
GLIC    Gloeobacter violaceus  
DPM   Disintegrations per Minute 
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CHAPTER I 
INTRODUCTION 
 
Nicotinic acetylcholine receptors (nAChRs) are cationic Cys-loop ligand-gated ion channel 
receptors characterized by their five subunit composition with each containing four 
transmembrane domains (M1-M4).1  The cation conducting receptors of the Cys-loop ligand-
gated ion channel superfamily are nAChR and serotonin (5HT3A).1  Sixteen different subunits 
makeup the nAChR subunit family with α4, α7 and β2 being some of the most common types in 
humans.2  Essential elements of the nAChRs include an amino terminus extracellular domain 
(ECD) containing a Cys-loop, three conserved transmembrane domains and a fourth more 
inconsistent transmembrane domain, an intracellular cytoplasmic loop between the third and 
fourth transmembrane domain, and a carboxyl terminus.1   
 
The entire ligand-gated ion channel superfamily, including GABA A, glycine, serotonin 
(5HT3A), some glutamate (GluCl), and acetylcholine receptors (AChR), holds vast 
pharmacological potential with their neurotransmitter-activated receptors impacting the central 
and peripheral nervous systems.3  nAChRs are known specifically for playing a role in 
neurodegenerative diseases such as Alzheimer disease and schizophrenia.  The function of 
nAChRs decrease with the progression of neurodegenerative disease, therefore understanding the 
receptor’s structure and the ligand binding domain is important for developing therapies.  Pursuit 
of structural understanding of the receptor has been underway for decades, although only 
relatively recently have crystallography and NMR techniques contributed with studies of model 
structures.  Full-length nAChR proteins cannot currently be produced at high enough 
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concentrations for high resolution structural studies.2  Attaining water-soluble models of the 
nAChRs would overcome limitations, such as hydrophobicity and instability, associated with 
crystallizing full-length transmembrane proteins.  In result, experimental procedures to generate 
water-soluble protein at great enough levels for crystallization and consequently drug therapy 
studies have been the focus of many studies.   
 
The quest for the production of potential drug designs for nAChRs began with the crystallization 
of a homologous receptor, the acetylcholine binding protein (AChBP).4  With 20-24% of the 
AChBP’s ECD being identical to the ECD of nAChRs, this structural data allowed for more 
insight into the nAChR construct.4  Crystallography of a bacterial ligand gated ion channel from 
Erwinia chrysanthemi (ELIC), now referred to as Dickeya dadantii, and Gloeobacter 
violaceus (GLIC) also allowed for a comparable analysis of the crystallized structure to 
nAChRs.5, 6  The next breakthrough for our understanding of nAChRs was the electron 
microscopy image generated from the muscle nAChR of Torpedo marmorata.7  Then in 2007, 
the nAChR subunit α1 ECD was crystallized while bound with α-bungarotoxin, an antagonistic 
neurotoxin.8  This study elucidated the role of essential components and residues for the binding 
of a ligand to the nAChR.   
 
Other studies have recently contributed to our overall comprehension of the ligand binding 
mechanism.  For example, glycosylation was found to be unessential for proper binding 
abilities.9  This was a significant discovery as it is easier to crystallize deglycosylated proteins.10  
nAChR studies have also concluded that replacing the hydrophobic Cys-loop region of the 
receptor with a similar hydrophilic section allows for better expression, but the proper subunit 
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association and receptor binding abilities have yet to be achieved.9  Replacing the Cys-loop of 
the nAChR with the Cys-loop of the AChBP allowed increased solubility and expression as 
well.11  However, the proper subunit association critical for binding abilities was impeded and 
the protein had low affinities for ligands.11  Concatamerized and truncated proteins have been 
created in hopes of producing proteins that have high expression yields, are soluble for 
crystallization purposes and retain the functional ability of the receptor with a high binding 
affinity for ligands.11, 12  Experiments have also been conducted to analyze the role of linkers in 
creating covalently bound subunits leading to operative receptors.9  While all of these 
advancements have led to a deeper understanding of nAChRs, low resolution structures and an 
inability to form pentameric structures in sufficient yield for crystallization have been continual 
obstacles.  
 
As we strive to create feasible water soluble receptors in order to produce crystallizable models, 
eliminating flexible regions of the subunits such as the M3M4 intracellular loop could be a 
possible way to create these models.13  Interestingly, the M3M4 intracellular loops of ligand-
gated ion channel bacterial homologs were found to be much smaller than the large intracellular 
loops in eukaryotic receptors.5, 6  It was then discovered that in 5HT3A receptors the native 
M3M4 loop was not essential for proper subunit assembly or receptor function.14  This same 
concept was applied to a nAChR and GluCl-β chimera and the truncated M3M4 loop allowed 
function unlike the results seen with a pure nAChR.14  However, when the entire loop was 
removed the receptor no longer functioned.14  It was concluded that at least a heptapeptide, as 
present in ELIC, was necessary for a feasible receptor.14  The M3M4 loop is a significant factor 
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to consider when constructing a water soluble model due to the fact that the loop is believed to 
play a role in proper receptor assembly and the desensitization of the receptor when activated.14    
 
Recent x-ray crystallography of 5HT3A, ionotropic glutamate receptor α (GluCl), and GABAA 
have also contributed to our understanding of the Cys-loop receptor superfamily.15-17  However, 
only homomers were crystallized still leaving questions on the assembly and structure of 
heteromers often seen in nAChRs.  The GluCl is of specific interest due to the similar folding of 
the transmembrane helices when compared to nAChRs.18  The amino acid sequence and protein 
structure of GluCl and nAChR are clearly related, but a discrepancy arises as the M2 and M3 
show significant variation.18  GluCl also has a serine residue believed to be critical in ligand 
binding and activation while nAChRs lack this residue.18  These inexplicable differences 
between nAChRs and GluCl are important to be aware of when studying the structures of the 
receptors and the mechanisms of function.  The crystallography of 5HT3A may hold even more 
importance in our pursuit to grasp the role of structure in the nAChR function.  5HT3A receptors 
are very similar to nAChRs and their comparability has been exploited as researchers have 
sought to create chimeric pentamer proteins with functional binding sites.19   A nAChR α7-
5HT3A chimera with a functional binding site was successfully produced while a homopentamer 
composed of α7 subunits lacked this property.19  This study has led to many investigations into 
the differences between the homologs.  Our study strives to contribute to this understanding as 
we search for key residues distinguishing the function of the α7 and 5HT3A receptors.            
 
As research continues to develop our understanding of Cys-loop receptors through crystallized 
structures, scientists have sought to determine how else we can manipulate the production of 
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nAChR through various model systems for heterologous expression of proteins.  Pichia pastoris, 
a yeast system, Spodoptera frugiperda, an insect system, and Xenopus laevis, a frog system, have 
all been used for research.  However, a limitation arose in the yeast models as expressing 
receptors with more than two subunits were not feasible.9  Our model system, Xenopus laevis, is 
particularly suited for this project as past research has shown that functioning heterologous 
receptors such as α4β2 can be produced.20  Having the ability to produce viable α4β2 receptors is 
an important property of Xenopus as this receptor is the most common type within the brain.21   
 
The significant advancements made throughout the Cys-loop receptor family has allowed us to 
gain much more insight into the structural basis of the function of nAChR receptors.  We know 
that the α4 and β2 subunits act together to form the binding region for the ligand.22   The α4 
subunit comprises most of the binding face and the Cys-loop is known to be essential for proper 
ligand association as well.22   However, our understanding of orthosteric ligand binding, where 
binding occurs at the active site of the protein, and its impact on the nAChRs receptors are still 
too limited for drug design.2  Our research studies the feasibility of creating high fidelity models 
of the ECD of nAChRs.  Water soluble designs offer the possibility of higher resolution 
structures than is possible with full-length transmembrane domain constructs consequently 
allowing for more defined crystallography models.13  These truncated designs of full length 
receptors will contribute to understanding how nAChR subunits fold and assemble and how their 
transmembrane domains affect structure and function.   
 
The first transmembrane domain (M1) of nAChR has been found to be specifically critical for 
the function of the neurotransmitter-binding extracellular domain.23  While M1 is fundamental in 
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heterodimer formation of nAChRs, the features of M1 that are essential for extracellular domain 
function have not been fully exploited.24  M1 sequences from ionotropic serotonin (5HT3A) and 
from α4, β2, and α7 nAChR subunits are similar but behave differently in ECD α4β2 nAChRs 
(Fig. 1).  The structural and sequence similarity between the two receptor families allows for 
structural comparison and analysis.   
m5HT3A       PLFYAVSLLLPSIFLMVVDIVGFCLPP 
Chα7M1       -LYYGLNLLIPCVLISALALLVFLLP- 
Humα4M1      PLFYTINLIIPCLLISCLTVLVFYL-- 
Humβ2M1      PLFYTINLIIPCVLITSLAILVFYL-- 
            *:* :.*::*.:::  : :: * * 
Figure 1. Protein comparison of the M1 domain from human α4, human β2, chicken α7, and 
mouse 5HT3A. 
 
 
 
Figure 2. [3H]epibatidine binding graph of α4α7M1 and β2α7M1 nAChR chimeras.  Concludes 
that α4β2 nAChRs M1 can be replaced by α7M1 and retain the [3H]epibatidine high affinity.23  
 
 
 
Figure 3. [3H]epibatidine graph of α4M/β2M1, α4(5HT3M1)/β2M, α4M1/β2(5HT3M1), and 
α4(5HT3M1)/β2(5HT3M1).  Concludes that α4β2 nAChRs M1 cannot be replaced by 5HT3M1 
and retain high [3H]epibatidine affinity.23 
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Experiments have shown that M1 from α4 and β2 nAChR subunits can be replaced with M1 
from the α7 subunit while maintaining the ligand binding function of the extracellular domain 
(Fig. 2).23  In contrast, replacing native M1 with M1 from the 5HT3A Cys-loop subunit abolishes 
ligand binding function (Fig. 3).23  Other particular amino acids, such as cysteines and prolines, 
have been found to be indispensable for the function of the nAChR extracellular domain.25  
Previous studies have also shown that the first half of M1 is critical for extracellular domain 
function.23  Our experiment will use this formative knowledge to guide our study of the nAChR 
M1 and its role in the receptor’s function.   
 
Through this research, we seek to determine amino acids in native M1 controlling expression of 
the ECD of α4β2 nAChR and amino acids from the 5HT3A M1 inhibiting that expression.  Our 
objectives are to identify the importance of M1 and guide the development of ECD Cys-loop 
receptors as water-soluble structural models of the full length transmembrane receptors.  With 
these intentions, we seek to advance toward our goal of understanding the structure and function 
of nAChR providing a foundation for developing drug therapies for neurological and psychiatric 
diseases for all Cys-loop receptors. 
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CHAPTER II 
METHODS 
 
Design of α7-5HT3A M1 Chimeras  
Beginning with protein comparisons using EMBOSS Water Pairwise Sequence Alignment based 
on the BLOSUM 62 matrix, the amino acids of the M1 regions of chicken (ch) nAChR α7 and 
mouse (m) 5HT3A were ranked according to their degree of similarity (Fig. 4). The colored 
residues represent most conserved to least conserved denoted by yellow to green to blue and 
finally red. 
Chα7M1      -LYYGLNLLIPCVLISALALLVFLLP- 
m5HT3A      PLFYAVSLLLPSIFLMVVDIVGFCLPP 
                                   *:*.:.**:*.::: .: :: * **  
Figure 4. An amino acid comparison of chα7 and m5HT3A M1. 
 
 
The amino acid disparities were then grouped into tentative parts ranging from a predicted 
preservation of ECD function to a predicted loss of function when converted from α7 to 5HT3A 
residues.  Ten distinct constructs were outlined using OMIGA with varying amounts of residue 
changes (Fig. 5).  The addition of yellow to green to blue to red residues represents the 
hypothesized progression of deleterious effects on the receptor.  The constructs were arranged in 
two ways: collective mutations, where the effects of the rising number of mutations can be seen, 
and independent mutations, where the effects of the different mutation types are seen 
individually.   
  Control α4M1α7     LYYGLNLLIPCVLISALALLVFLLP        Control β2M1α7    LYYGLNLLIPCVLISALALLVFLLP 
Part1α4M1α7-5HT3A    LFYGVNLLLPCILLSAVAIVVFLLP      Part1β2M1α7-5HT3A   LFYGVNLLLPCILLSAVAIVVFLLP  
Part1bα4M1α7-5HT3A   LFYGVNLLLPCILISALALLVFLLP      Part1bβ2M1α7-5HT3A  LFYGVNLLLPCILISALALLVFLLP 
Part1cα4M1α7-5HT3A   LYYGLNLLIPCVLLSAVAIVVFLLP      Part1cβ2M1α7-5HT3A  LYYGLNLLIPCVLLSAVAIVVFLLP 
Part2α4M1α7-5HT3A    LFYGVNLLLPCIFLMVVAIVGFLLP       Part2β2M1α7-5HT3A  LFYGVNLLLPCIFLMVVAIVGFLLP 
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Part2bα4M1α7-5HT3A   LYYGLNLLIPCVFIMVLALLGFLLP      Part2bβ2M1α7-5HT3A  LYYGLNLLIPCVFIMVLALLGFLLP 
Part3α4M1α7-5HT3A    LFYAVSLLLPCIFLMVVAIVGFLLP       Part3β2M1α7-5HT3A  LFYAVSLLLPCIFLMVVAIVGFLLP 
Part3bα4M1α7-5HT3A   LYYALSLLIPCVLISALALLVFLLP      Part3bβ2M1α7-5HT3A  LYYALSLLIPCVLISALALLVFLLP 
Part4α4M1α7-5HT3A    LFYAVSLLLPSIFLMVVDIVGFLLP       Part4β2M1α7-5HT3A  LFYAVSLLLPSIFLMVVDIVGFLLP 
Part4bα4M1α7-5HT3A   LYYGLNLLIPSVLISALDLLVFLLP      Part4bβ2M1α7-5HT3A  LYYGLNLLIPSVLISALDLLVFLLP  
Figure 5. Ten chα7-m5HT3A chimeric constructs designed to cause progressive loss of ECD 
function. 
 
 
Construction of nAChR Chimeras  
Using DNA synthesis services, DNA 2.0 and IDT, the site-directed mutations from chα7 to 
m5HT3A amino acids established through the sequence studies were synthesized.  The DNA 
then underwent a bacterial transformation using One Shot® OmniMAX™ 2 T1 Chemically 
Competent E.coli (Invitrogen) cells.  After obtaining a sufficient amount of DNA in bacteria, a 
QIAfilter® Plasmid Midi Prep Kit (Qiagen) was performed to purify the DNA.  To ensure the 
desired designs were produced double digestions were performed.  The sequence of the chα7-
m5HT3A M1 chimera within the DNA 2.0/IDT vector was then cleaved using the restriction 
enzymes EagI-HF and MluI and BstXI and MluI (New England BioLabs) for the α4 and β2 
constructs, respectively.  The double digest gels from the previous step were consequently 
isolated using Zymoclean™ Gel DNA Recovery Kit (Zymo Research).  α4β2 α7-5HT3A M1 
chimeras were then ligated with the ECD of human α4 and human β2 subunits in a pSP64 
Poly(A) vector (Promega) using T4 DNA Ligase (New England BioLabs).  A bacterial 
transformation was performed with the newly made chimera and the Zyppy™ Plasmid Miniprep 
Kit (Zymo Research) was used to purify the DNA.  Double digestions were then done to ensure 
the proper sequences were present.  After confirming the presence of the desired gene product, 
QIAfilter® Plasmid Midi Prep Kit (Qiagen) was used to purify a greater amount of DNA.  Lone 
Star Labs DNA sequencing was then used to verify that the proper sequences were present.  The 
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vectors were then linearized using restriction enzymes AseI and PvuII to cut the α4 and β2 
constructs, respectively, and Ambion mMessage mMachine® SP6 Kit was used to produce RNA 
from the linearized DNA.  Gel electrophoresis was used throughout this process to confirm the 
presence of appropriate band lengths and consequently the presence of the correct DNA and 
RNA.   
 
Xenopus Oocyte Injections and Protein Production 
Oocytes were surgically extracted from Xenopus laevis and were prepared using collagenase type 
I (Invitrogen) in order to remove the vascular layer incasing the oocyte.  A 40 nl aliquot 
containing 20 ng of the nAChR chimera RNA was injected into the cytoplasm of the vegetal pole 
of each oocyte.  This procedure was replicated for each designed subunit construct.  The oocytes 
were then incubated at 18°C for 3 days in 50% Leibovitz’s L-15 medium (Invitrogen) in 10 mM 
HEPES (Sigma), pH 7.5, containing 10 units/ml penicillin (Invitrogen), 10 µg/ml streptomycin 
(Invitrogen), and 43 µg/ml gentamicin (Invitrogen).  Following this step, the desired protein 
product was isolated by homogenizing 25-50 oocytes by hand in an ice-cold buffer (Buffer A: in 
mM: 50 sodium phosphate, 50 NaCl, 5 EDTA, 5 EGTA, 5 benzamidine, 15 iodoacetamide, pH 
7.5), centrifuging the solution for 30 minutes at 14,500 x g at 4°C, and consequently solubilizing 
the pellet in a buffer (Buffer B: Buffer A with 2% w/v Triton X-100) with gentle agitation for 2 
hours at 4°C.  Centrifugation was then repeated (30 minutes, 14,500 x g, 4°C) and the detergent 
extract containing the anticipated protein product was consequently removed.  The isolated 
supernatant was then divided for use in immunoblotting and ligand binding assays. 
 
[3H]Epibatidine Testing 
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Ligand binding assays with [3H]epibatidine were conducted to identify the ligand dissociation 
constant and the yield of the resulting ECD receptors.  The ligand dissociation constant measures 
the fidelity of the ECD structure to the structure of the full length receptor.  The yield of ECD 
receptors compared to the yield of the full length receptor measures how efficiently the truncated 
subunits were assembled.  Immulon 4 HBX plastic microwells (Thermo Labsystems) for solid 
phase binding assays were coated with the primary antibody which was diluted in 10 mM 
CAPSO to a concentration of 4µg/ml of CAPSO and incubated for 3 days.  The wells were 
subsequently washed with NaN3-PBS.  After the wash, the wells were blocked with 3% bovine 
serum albumin, fraction V (EM Science), in PB +S (in mM: 137 NaCl, 2.7 KCl, 1.4 KH2PO4 10 
Na2HPO4), incubated for 2 hours and washed with wash buffer.  A volume of detergent extract 
from 0.1 to 0.5 injected oocytes was added to the primary antibody-coated microwells.  The 
microwells were incubated overnight at 4°C for proper binding to occur and then washed with 
ice cold buffer B.  100 µl of (±)-[3H]epibatidine  (PerkinElmer Life Sciences; specific activity: 
55.8 Ci/mmol) in ice-cold buffer B was then added to each microwell and incubated overnight at 
4°C for the purpose of measuring the [3H]epibatidine binding.  The microwells were washed 
again with ice-cold buffer B and stripped with a solution of 5% SDS and 25 mM dithiothreitol in 
buffer B.   A liquid scintillation counter was used to measure the amount of [3H]epibatidine 
bound for each sample.  Data was recorded as the average of duplicate and triplicate 
measurements.   
 
Immunoblotting Analysis 
The presence of the protein product was determined through immunoblot analysis using the mAb 
142 and mAb 236 epitope tags for the α4 and β2 chimeras, respectively.  Beginning with a 5 
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minute 65°C denaturation period with 1% SDS and 15 mM dithiothreitol, the samples were then 
separated by SDS-PAGE on a 12.5% acrylamide gel.  Using Bio-Rad Precision Plus- Dual Color 
(20 µl) for visualization purposes, the gel was run at 15 milliamps for 65 minutes and 
subsequently 30 milliamps for 90 minutes.  The Immun-Blot™ polyvinylidene difluoride 
(PVDF) membrane (BioRad) was wetted with 100% methanol and then run at 30V for 30 
minutes using a GENIE® electrophoretic transfer device (Idea Scientific) in order for protein 
transfer to occur.  After completion of the run, the membrane was re-wetted with methanol to 
minimize movement of proteins on the membrane.  Overnight, the membrane was then blocked 
at 4°C with blocking buffer (5% powdered milk in PBS buffer and 0.05% Tween®20.  The 
primary antibody, Monoclonal Anti-Nicotinic Acetylcholine Receptor, α4 subunit, Clone 
mAb142 (Sigma) was diluted 1:10,000 in blocking buffer and incubated with the membrane 
overnight at 4°C while continuously rocked.  Wash buffer (PBS and 0.05% Tween) washed the 
membrane three times for one hour per wash.  The secondary antibody, ImmunoPure® Goat 
Anti-Rat IgG, (H+L), Peroxidase Conjugated (Pierce), was diluted 1:5000 in blocking buffer and 
incubated with the membrane overnight at 4°C.  Again, the washing procedures were repeated.  
The SuperSignal West Dura Extended Duration Substrate (Pierce) was used in accordance with 
the standard protocol so as to visualize the protein products on BioMax ML film (Eastman 
Kodak Co.).  
 
The gel was then stripped using Restore Western Blot Stripping Buffer (Thermo Scientific).  The 
blot was covered in the stripping buffer and incubated for 15 minutes at 37ºC.  After, the blot 
was washed three times at 30 minutes each with wash buffer.  The western blot procedure 
outlined above was repeated beginning with the blocking buffer.  The β2 antibody, mAb236, was 
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diluted to 1:12,000 in blocking buffer and then the secondary antibody ImmunoPure® Goat Anti-
Rat IgG, (H+L), Peroxidase Conjugated (Pierce), was diluted 1:5000 in blocking buffer.  
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CHAPTER III 
RESULTS 
 
Ligand Binding Assay 
The binding abilities of the produced proteins were tested using an [3H]epibatidine binding 
assay.  A liquid scintillation counter determined the amount of [3H]epibatidine bound to the 
nAChR chimeras by analyzing the amount of radioactivity present.  The [3H]epibatidine had a 
specific activity of 55.8Ci/mol and was added to microwells of oocyte lysate at a 1.0 nM 
concentration. The disintegrations per minute (DPM) were measured and used to calculate the 
bound [3H]epibatidine per oocyte determining the receptor’s function.   
 
α7 M1 was used to create a homopentameric M1 in α4β2 subunits in an attempt to create a 
heteromer with a single M1 structure similar to the 5HT3A structure.  The large number of 
residue similarities among the nAChR subunits and previous studies on α4α7M1 and β2α7M1 
predicted that the chimera would retain the native binding ability.  The ligand binding values 
seen above each histogram bar measure the yield of functional receptors (Fig. 6).  The ligand 
binding assay determined that α4α7M1 and β2α7M1 had decreased [3H]epibatidine binding 
compared to the native α4β2 M1 receptor.  This was unexpected and consequently defines the 
few mutated residues of the α4β2 M1 as important for the high binding ability of α4β2 M1 
receptors.     
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Figure 6. α4α7M1 and β2α7M1 had decreased [3H]epibatidine binding compared to the native 
α4 and β2 M1 subunits with a decrease of approximately ten-fold of the ligand binding ability 
(fmol/oocytes).     
  
 
After analyzing the variances between the 5HT3A M1 and α7 M1, the disparities of the amino 
acid characteristics were ranked from a predicted conservation of function to a predicted loss of 
function.  Yellow mutations represented a hypothesized insignificant mutation with respect to 
binding ability.  The mutation succession extended to green, blue, and finally red which was 
predicted to consist of deleterious mutations.  It was hypothesized that as mutations with 
dissimilar properties compared to the native amino acids were added in binding ability would 
decrease.  The [3H]epibatidine binding assay confirmed this prediction as mutations with 
severely disparate characteristics compared to the native residue created a large decrease in 
function (Fig. 7).  The yellow mutations, however, did not have as great of a negative effect on 
the receptor binding.  The binding assay concluded that mutations with dissimilar characteristics 
compared to native residues create greater unfavorable effects on protein function than residues 
with similar properties.    
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Figure 7. Compared to the control, α4α7M1 and β2α7M1, adding in 5HT3A residues with a 
progressive change from the native amino acid characteristic caused a gradual decrease in 
[3H]epibatidine binding.    
 
 
The collective progression of mutations from yellow to red was predicted to cause diminished 
[3H]epibatidine binding due to the accumulation of altered residues.  It was concluded that as the 
quantity of mutations increased, the ligand binding ability decreased compared to the control, 
α4α7M1 and β2α7M1 (Fig.8).  The yellow mutations caused a larger decrease in binding ability 
than predicted.  With the high conservation of native characteristics in the yellow mutations, we 
expected retention of the binding ability of the control.  These unexpected results may be due to 
residue interactions in subunit assembly.   
A. LYYGLNLLIPCVLISALALLVFLLP 
B. LFYGVNLLLPCILISALALLVFLLP 
C. LYYGLNLLIPCVLLSAVAIVVFLLP 
D. LYYGLNLLIPCVFIMVLALLGFLLP 
E. LYYALSLLIPCVLISALALLVFLLP 
F. LYYGLNLLIPSVLISALDLLVFLLP 
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Figure 8. Compared to the control, α4α7M1 and β2α7M1, as the α7 to 5HT3A mutations were 
made a decrease in [3H]epibatidine binding was observed.    
  
 
A pentamer composed of five mutated subunits resulted in decreased binding abilities in all 
mutated constructs.  However, it was predicted that constructing a receptor from both native and 
mutated subunits would result in higher binding abilities.  The [3H]epibatidine determined the 
combinatorial effect of native and mutated subunits to increase binding ability (Fig. 9).  When 
one of the subunit types, α4 or β2, was composed of a native M1, the function of the receptor 
increased.  Consequently, native subunits may aid in the proper folding and function of nAChR 
with chimeric subunits. 
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Figure 9. Heteromers composed of both mutated α4 β2 subunits had decreased binding 
compared to receptors with one native subunit type.    
 
 
Immunoblotting 
In order to induce protein expression, the truncated nAChRs with varying levels of mutagenesis 
were injected into the Xenopus laevis oocytes.  The positive controls conducted alongside the 
mutated constructs were α4M1α7 and β2M1α7.  The negative control contained only uninjected 
oocytes.  Using a 12.5% acrylamide gel, the proteins were purified and separated.    
Immunoblotting was conducted with the mAb142 and mAb236 antibody to identify the α4 and 
β2 subunits, respectively (Fig. 10 and 11).   
 
The control and mutant constructs were predicted to have equivalent amounts of total protein 
present.  The immunoblots confirmed the presence of protein.  However, the protein 
concentrations were not uniform throughout the mAb142 and mAb236 blots.  The variation in 
protein may be due to differential protein degradation rates of the constructs.  Further 
investigation will be needed to conclude the cause of the disparity in protein concentrations.  
 
 
Figure 10. Immunoblot analysis displays a sufficient amount of protein present for each 
construct identified with the α4 mAb142 tag. 
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Figure 11. Immunoblot analysis displays a sufficient amount of protein present for each 
construct identified with the β2 mAb236 tag.  
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CHAPTER IV 
CONCLUSIONS 
 
Viability of a Homomeric M1 within Truncated α4β2 Subunits  
5HT3A and α7 nAChR are both homomeric receptors.  Understanding the assembly of 
homomeric receptors will contribute to our comprehension of the complex assembly of 
heteromeric receptors such as α4β2 receptors.  In order to fully grasp the role of M1 in not only 
ECD function but subunit assembly, it is critical to determine if a homomeric M1 is viable in 
α4β2 receptors.  While previous studies have shown that α4M1α7 and β2M1α7 retain function at 
a level comparable to the native α4M1 and β2M1 (Fig. 2), our results showed that this M1 
substitution caused a large decrease in function (Fig. 6).  It was assumed that α4M1α7 and 
β2M1α7 would be a reliable starting point with high expression based on the previous 
experimental results and high homology.  Nevertheless, there was enough binding ability present 
to continue with the α7-5HT3A mutagenesis and study the effect of additional mutations on 
nAChR’s M1.  The unpredicted results have led to further questioning of what composes a 
feasible M1.  Future studies will assess whether α4 M1 replacing the β2 M1 creates a viable 
receptor and reciprocally for the α4 receptor.         
 
α4β2 Subunit Roles in Receptor Assembly 
Our α4M1α7 and β2M1α7 results revealed that altering a native M1 to an exceedingly similar 
M1 will inhibit proper subunit assembly.  This was unexpected as we had predicted the small 
number of mutations would have an insignificant effect on the ligand binding ability.  We then 
sought to study the combinatorial effect of native and mutated subunits forming heteromeric 
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proteins (Fig. 9).  When both α4M1 and β2M1 were mutated, there was a substantial decrease in 
ECD function.  However, when one of the subunit types, α4 or β2, was composed of a native 
M1, the binding ability increased.  This is significant because it shows a potential relationship in 
native subunits aiding the assembly of a functional receptor even in the presence of mutations.  
Additional structural and protein folding studies will have to be conducted, but native subunits 
may assist in the proper folding and function of chimeric nAChRs.     
 
Effect of Mutations on ECD Function 
The [3H]epibatidine binding results concluded that mutations with severely disparate 
characteristics compared to the native residue created a large decrease in function.  This was 
expected, as adding in a residue with a substantial variation in charge or size would undoubtingly 
affect the protein structure.  However, the reduction of function seen with mutations to similar 
residues was unexpected.  While the amino acid changes to analogous nonpolar residues were 
not predicted to affect the protein structure, our results led us to conclude that these appearingly 
insignificant mutations impacted the overall folding of the protein.  In summary, the α7 amino 
acid conversions to 5HT3A were ranked from unfavorable effects (yellow) to deleterious effects 
(red) and these results were then visualized on the M1 structure (Fig. 12).  This structure allows 
the layout of the ranging mutations and the possible protein interactions that could be affected by 
specific mutations to be conceptualized.       
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Figure 12. The [3H]epibatidine binding results were used to determine the mutations most 
detrimental to ECD function.  These conclusions were then applied to the three-dimensional 
structure of the M1 allowing residual interactions to be visualized.   
  
  
A specific mutation of interest when considering residual interactions was the conversion of 
cysteine to serine in Part 4.  This mutation is significant as a large quantity of Cys-loop receptors 
have this cysteine present alongside a proline.  With the strong residual conservation throughout 
the receptor family, it was assumed that this mutation would have a negative effect on the 
feasibility of the M1.  This was seen to be true and leads us to continue questioning what role 
this residue plays in transmembrane domain assembly as well as subunit assembly.    
 
After analyzing the M1 amino acid composition, another residue of particular importance was 
distinguished.  The proline at the front of the M1 structure is conserved in α4, β2, and 5HT3A 
Alpha: LFYAVSLLLPSIFLMVVDIVGFLLPATR   
Beta:  LFYAVSLLLPSIFLMVVDIVGFLLPATR 
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(Fig. 13).  Notably, there is a threonine present at this location in the α7 M1.  This discrepancy 
allows us to ponder whether reverting this residue back to the α4β2 native proline would create a 
higher functioning α4M1α7 and β2M1α7 construct. 
 
Figure 13. The sequence alignment of 5HT3A, α7, α4, and β2 highlighting the dissimilarity of the 
α7 proline and 5HT3A, α4, and β2 threonine. 
 
 
Not only do the α7 to 5HT3A mutations guide our insight into nAChR ECD function but 
additionally 5HT3A ECD function.  While truncated ECD α4β2 receptors have been produced, a 
5HT3A ECD structure has yet to be constructed.  Our results will aid in future compositions of 
truncated 5HT3A structures allowing high resolution crystallized structures to be created.     
 
The results of our [3H]epibatidine binding assay allowed us to distinguish which amino acids 
were potentially important in the nAChR M1 and which 5HT3A residues could be considered 
detrimental to a nAChR M1.  This data will advance structural studies attempting to understand 
the full-length nAChR and Cys-loop receptor superfamily as a whole.  With the progression of 
our comprehension of receptor assembly, binding, and function, we aspire to develop novel 
truncated proteins retaining the characteristics of the full-length receptors.  Resultantly, we seek 
to crystallize these structures aiding the development of possible drug design targeting the many 
diseases affected by the Cys-loop receptors.      
 
 
LGICdbp: 5HT3Amumu-1 -ISNSYAEMKFYVIIRRRPLFYAVSLLLPSIFLMVVDIVGFCLPPDSGERVSFKITLLLG 
LGICdbp: ACHa7gaga CCKEPYPDITFTVTMRRRTLYYGLNLLIPCVLISALALLVFLLPADSGEKISLGITVLLS 
LGICdbp: ACHa4hosa CCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLS 
LGICdbp: ACHb2hosa -DDSTYVDITYDFIIRRKPLFYTINLIIPCVLITSLAILVFYLPSDCGEKMTLCISVLLA  
       . * ::.: . :**  *:* :.*::*.:::  : :: * ** :.**:::: *::**. 
 
* = conserved amino acid   : = conservation of amino acid properties   . = semi-conservation of amino acid properties       
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